United Therapeutics (NASDAQ:UTHR) CEO Sells $5,145,580.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $541.64, for a total value of $5,145,580.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $175,731,306.52. The trade was a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

United Therapeutics Stock Down 2.2%

Shares of United Therapeutics stock opened at $532.78 on Friday. The stock’s 50-day simple moving average is $511.37 and its 200-day simple moving average is $539.93. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35. The company has a market capitalization of $22.85 billion, a price-to-earnings ratio of 19.06, a PEG ratio of 2.73 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.41 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Callan Family Office LLC purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $1,217,000. Nicholas Investment Partners LP raised its holdings in shares of United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $3,359,000. Andra AP fonden lifted its stake in shares of United Therapeutics by 33.5% during the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after acquiring an additional 8,760 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new position in United Therapeutics during the 4th quarter valued at $633,000. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of United Therapeutics in a research report on Thursday, September 24th. They set a “sell” rating and a $321.00 price objective on the stock. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of United Therapeutics in a research note on Thursday, October 1st. Morgan Stanley lifted their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $627.31.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.